An open-label Optional Titration Trial to Evaluate the Efficacy, Tolerability and Safety of Valsartan in Patients with Mild to Moderate Essential Hypertension Treated for 8 Weeks in the Lagos University Teaching Hospita

An eight-week open-label optional titration trial to evaluate the efficacy, tolerability and safety of Valsartan 80 mg/ & 160 mg once daily was carried out in patients with mild to moderate essential hypertension at the Lagos University Teaching Hospital. There was a significant reduction in both systolic and diastolic blood pressure without reflex tachycardia. Only 5(8%) developed self limiting side effects known to be associated with the use of Valsartan. 3(5%) patients reported improvement in their quality of sleep. There were no significant changes in haematological counts. Biochemistry was normal at the end of the study except serum glutamate transaminase (SGPT) which although was found to be significantly higher at the end of the study, did not induce any clinical signs of symptoms or require therapeutic intervention. This study demonstrates the tolerability and efficacy of Valsartan in the treatment of mild to moderate hypertension in Nigerians. Key words: Valsartan, hypertension, Tolerability and efficacy. Nigerian Medical Practitioner Vol.47(4) 2005: 65-6

Control derivative to optimal control analysis

Optimal control theory, generally, is to determine the control signals which will cause a process to satisfy the physical constraints and at the same time optimize some performance criterion. In this work, a numerical method for finding solution to linear optimal control problems with bounded state constraints is examined. The method applied is based on Legendre series by parameterization of both the state and the control variables involving a derivative.Journal of the Nigerian Association of Mathematical Physics, Volume 15 (November, 2009), pp 399 - 40

Population health outcomes in Nigeria compared with other west African countries, 1998-2019: a systematic analysis for the Global Burden of Disease Study.

BACKGROUND: Population-level health and mortality data are crucial for evidence-informed policy but scarce in Nigeria. To fill this gap, we undertook a comprehensive assessment of the burden of disease in Nigeria and compared outcomes to other west African countries. METHODS: In this systematic analysis, using data and results of the Global Burden of Diseases, Injuries, and Risk Factors Study 2019, we analysed patterns of mortality, years of life lost (YLLs), years lived with disability (YLDs), life expectancy, healthy life expectancy (HALE), and health system coverage for Nigeria and 15 other west African countries by gender in 1998 and 2019. Estimates of all-age and age-standardised disability-adjusted life-years for 369 diseases and injuries and 87 risk factors are presented for Nigeria. Health expenditure per person and gross domestic product were extracted from the World Bank repository. FINDINGS: Between 1998 and 2019, life expectancy and HALE increased in Nigeria by 18% to 64·3 years (95% uncertainty interval [UI] 62·2-66·6), mortality reduced for all age groups for both male and female individuals, and health expenditure per person increased from the 11th to third highest in west Africa by 2018 (US$18·6 in 2001 to$83·75 in 2018). Nonetheless, relative outcomes remained poor; Nigeria ranked sixth in west Africa for age-standardised mortality, seventh for HALE, tenth for YLLs, 12th for health system coverage, and 14th for YLDs in 2019. Malaria (5176·3 YLLs per 100 000 people, 95% UI 2464·0-9591·1) and neonatal disorders (4818·8 YLLs per 100 000, 3865·9-6064·2) were the leading causes of YLLs in Nigeria in 2019. Nigeria had the fourth-highest under-five mortality rate for male individuals (2491·8 deaths per 100 000, 95% UI 1986·1-3140·1) and female individuals (2117·7 deaths per 100 000, 1756·7-2569·1), but among the lowest mortality for men older than 55 years. There was evidence of a growing non-communicable disease burden facing older Nigerians. INTERPRETATION: Health outcomes remain poor in Nigeria despite higher expenditure since 2001. Better outcomes in countries with equivalent or lower health expenditure suggest health system strengthening and targeted intervention to address unsafe water sources, poor sanitation, malnutrition, and exposure to air pollution could substantially improve population health. FUNDING: The Bill & Melinda Gates Foundation

The Lancet Nigeria Commission: investing in health and the future of the nation.

Funder: Wellcome TrustHealth is central to the development of any country. Nigeria’s gross domestic product is the largest in Africa, but its per capita income of about ₦770 000 (US$2000) is low with a highly inequitable distribution of income, wealth, and therefore, health. It is a picture of poverty amidst plenty. Nigeria is both a wealthy country and a very poor one. About 40% of Nigerians live in poverty, in social conditions that create ill health, and with the ever-present risk of catastrophic expenditures from high out-of-pocket spending for health. Even compared with countries of similar income levels in Africa, Nigeria’s population health outcomes are poor, with national statistics masking drastic differences between rich and poor, urban and rural populations, and different regions